COPD: SYMBICORT 160/4.5 mcg is used long-term to improve symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, for better breathing and fewer flare-ups.

2024年4月8日 · Symbicort inhaler contains a combination of budesonide and formoterol and is used for asthma and chronic obstructive pulmonary disease (COPD). Budesonide is a corticosteroid that reduces inflammation in the body. Formoterol is a long-acting bronchodilator that relaxes muscles in the airways to improve breathing.

2023年8月31日 · A specific strength of Symbicort (160/4.5) may be used as a maintenance treatment in people with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema, to reduce inflammation and airflow obstruction. Having two medications in one inhaler is more convenient than having to take two inhalers.

SYMBICORT 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce COPD exacerbations. SYMBICORT is NOT indicated for the relief of acute bronchospasm.

Symbicort® (budesonide and formoterol fumarate dehydrate) is a medicine that contains multiple drugs for treating chronic obstructive pulmonary disease (COPD). This type of medicine is also called combination therapy. 1. Symbicort contains budesonide, an inhaled corticosteroid (ICS), and formoterol, a long-acting beta2-adrenergic agonist (LABA). 1

2025年2月26日 · SYMBICORT 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce COPD exacerbations.

Budesonide-formoterol (brand name, Symbicort; AstraZeneca) is a maintenance treatment used to prevent bronchospasm (airway narrowing) caused by COPD. It is a combination of an inhaled corticosteroid (budesonide) that reduces inflammation, and a long-acting bronchodilator (formoterol) that relaxes airway muscles.

2006年1月2日 · The fixed combination of budesonide–formoterol in a single dry powder inhaler (Symbicort ® Turbuhaler ® [hereafter referred to as budesonide–formoterol]; AstraZeneca UK Limited) has been instructed to patients with COPD as an alternative to treatment of concurrent inhaled corticosteroid and a long-acting β 2-agonist, administered via ...

COPD: SYMBICORT 160/4.5 mcg is used long-term to improve symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, for better breathing and fewer flare-ups.

2017年9月14日 · The US Food and Drug Administration (FDA) has approved an update to the label of chronic obstructive pulmonary disease (COPD) treatment budesonide/formoterol fumarate dehydrate (SYMBICORT) to indicate its reduction of COPD exacerbations.